Research process of the neuropeptide VGF as a novel antidepressant regulatory factor.
- Author:
Jiejie GUO
1
;
Chuang WANG
;
Qinwen WANG
Author Information
1. Ningbo University School of Medicine, Ningbo 315211, China.E-mail: gjj_19880608@126.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Antidepressive Agents;
Depression;
physiopathology;
Humans;
Neurogenesis;
Neuropeptides;
physiology;
Synaptic Transmission
- From:
Journal of Southern Medical University
2014;34(2):279-282
- CountryChina
- Language:Chinese
-
Abstract:
As a major cause of disability, depression is expected to become the second highest burden of disease worldwide by the year 2020. The shift of research in depression from monoamine hypothesis to the realm of neurotrophic hypothesis, neural plasticity hypothesis, and enhancing neurogenesis as an antidepressant-like agent brings about crucial insights to find novel mediator of antidepressant activity. Studies have shown that the neuropeptide VGF participates in the regulation of hippocampal neurogenesis and neuroplasticity and also plays an important role in the regulation of neuronal proliferation and survival, suggesting that the neuropeptide VGF may be a novel regulator in antidepressant treatment. The authors review the latest progress in the regulatory mechanisms of neuropeptide VGF on neurogenesis, neurotrophic and synaptic activity in depression. Further understanding of the role of neuropeptide VGF in depression can identify novel targets for pharmacological interventions.
